Under a new district proposal, HISD's gifted students would have to meet new academic requirements to attend Carnegie ...

STAAR Surgical Company , a leading developer, manufacturer, and marketer of the EVO family of Implantable Collamer® lenses (EVO ICLtm) for myopia, astigmatism and presbyopia, is proud to announce a ...

Operator: Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a reminder, this event is being ...

Staar Surgical STAA will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Staar Surgical to ...

Computational chemistry describes the use of computer modelling and simulation – including ab initio approaches based on quantum chemistry, and empirical approaches – to study the structures ...

The FDA agreed that Sangamo could use data from its ongoing Phase I/II STAAR trial (NCT04046224) as a primary basis for accelerated approval of isaralgagene civaparvovec—specifically ...

The first catalyst which would be the release of intermediate eGFR slope data at 52 weeks from the phase 1/2 STAAR study in the 1st half of 2025. From there, if this endpoint goes well ...

Nuclear chemistry is concerned with the properties of and changes to atomic nuclei, as opposed to traditional chemistry, which involves properties and changes related to the electronic structure ...

U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding ...

The FDA has agreed in a Type B interaction that data from the ongoing Phase 1/2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using eGFR slope at ...

U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement ...